Tag: Epicutaneous Immunotherapy (EPIT)

Moonlight Therapeutics Microneedle Patch

Study Finds Microneedle Delivery Successful in Test of Peanut Allergy Immunotherapy

Study finds five-minute weekly dose of peanut protein through the skin, delivered by a novel microneedle technology, was superior in desensitizing peanut-allergic mice compared to administering the protein through a skin patch.
Viaskin Patch

Viaskin Peanut Patch Therapy Delayed Further as DBV Readies Another Phase...

The patch therapy remains in regulatory limbo.
Viaskin-Patch

Safety of Viaskin Peanut Patch Therapy Improved Over 3-Year Study

Reactions decreased over study duration.
Viaskin Peanut

FDA Wants More Viaskin Peanut Data Resulting in Further Approval Delays

Delays mount pushing trials of modified patch.
Moonlight Therapeutics Microneedle Patch

New Microneedle Patch Therapy for Food Allergies Takes Step Forward

Painless microneedle patch may provide new method for desensitization.
DBV Patch Closeup

DBV, Developers of Patch Therapies for Allergies to Peanuts, Milk and...

The company announced they would be laying off 200 employees in Q1.
Viaskin Patch

Will the Viaskin “Patch” Therapy for Peanut Allergy be Approved Soon?...

Company is restructuring in anticipation of delays.
Viaskin-Patch

FDA Advisory Committee Meeting to Review Viaskin Peanut for the Treatment...

Next step in the approval process for the therapy scheduled for May 15, 2020.
Viaskin Peanut

DBV Technologies Reports Positive Three-Year, Long Term Data from Phase III...

Patients demonstrated durable, long-term clinical benefit with an additional two years of treatment.
Viaskin Peanut

DBV Technologies Announces FDA Acceptance of BLA filing for Viaskin Peanut...

If approved, Viaskin Peanut would be the first and only epicutaneous immunotherapy indicated for this potentially life-threatening condition in children.